Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis

2020/04/16 by Ariane Klein, Kirsten Minden, Anton Hospach +7 · 20 citations
Medicine · Health Professions · #Autoimmune and Inflammatory Disorders Research #Adolescent and Pediatric Healthcare #Ocular Diseases and Behçet’s Syndrome

paper · doi:10.1136/annrheumdis-2019-216843

Citations

• Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis

Cited by

• Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial
• Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group. [europepmc]
• Persistence and adherence to biologic therapies in juvenile idiopathic arthritis. [europepmc]
• Spectrum of Clinical Research in Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis of Registered Studies in Clinicaltrials.gov and Clinicaltrialsregister.eu. [europepmc]
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. [europepmc]
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. [europepmc]
• Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial. [europepmc]
• Capturing critical data elements in Juvenile Idiopathic Arthritis: initiatives to improve data capture. [europepmc]
• Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible? [europepmc]
• Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. [europepmc]
• Why and How Should We Assess the Cardiovascular Risk in Patients with Juvenile Idiopathic Arthritis? A Single-Centre Experience with Carotid Intima-Media Measurements. [europepmc]
• Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis. [europepmc]
• Treat-to-target strategies for the management of familial Mediterranean Fever in children. [europepmc]
• Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis. [europepmc]
• Patients with Adult-Onset Still's Disease in Germany: A Retrospective Analysis of Clinical Characteristics and Treatment Practices Ahead of the Release of the German Recommendations. [europepmc]
• Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis. [europepmc]
• Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review. [europepmc]
• Increasing access without compromising quality: optimizing telemedicine care in pediatric rheumatology. [europepmc]
• [Juvenile idiopathic arthritis-persistent oligoarticular subtype : Consensus-based treatment recommendations as part of the ProKind Rheuma Initiative]. [europepmc]
• PRO-KIND consensus protocol for classification, monitoring, and therapy in pediatric rheumatology: persistent oligoarticular juvenile idiopathic arthritis. [europepmc]